Font Size

Screen

Profile

Layout

Direction

Menu Style

Cpanel

Anti-cancer effect of ICD-85(venom derived peptides) on MDA-MB231 cell line (in vitro) and experimental mice with breast cancer (in vivo)

  • PDF

 

Abstract:

Breast cancer has become common in developing and developed countries. Alarming increase in this disease as a leading cause of death in women is a concern of all. Despite the significant improvements in the management of breast cancer, the survival rate is not more than 20% - 25%. For this study, MDA-MB231 cell line was used and the effect of ICD-85 (biologically active peptides from venomous animals) was assayed by measuring the activity of the cytosolic enzyme lactate dehydrogenase(LDH) released into the culture medium after membrane legions. Morphological changes of cells were checked in control and cells incubated with ICD-85 as chemo preventive agent.
Results showing in test groups - incubation with 10μg/ml dose of ICD-85 had decreased cytoplasmic branch. Some cells were ruptured and lost the continuity of their surrounding membranes, and number of cells was decreased. On the other hand, when ICD-85 was used as an anticancer treatment of mice with breast cancer, it was shown that ICD-85 can prevent the growth of breast tumor, increase the life duration of experimental mice and inhibit angiogenesis in breast tumor as compared with control group. It seems that ICD-85 acts at the membrane level and can prevent the cell growth as well as producing apoptosis (cell suicide) for breast cancer cells.

 

Attachments:
FileFile sizeDownloadsLast modified
Download this file (anticancer ICD-85 2009-1.pdf)anticancer ICD-85 2009-1.pdf415 Kb64514/01/13 05:09

Last Updated on Monday, 14 January 2013 05:10

You are here: Paper and Publication venom and cancer paper Anti-cancer effect of ICD-85(venom derived peptides) on MDA-MB231 cell line (in vitro) and experimental mice with breast cancer (in vivo)